Physician profile
Michael G Vanderloo
NPI 1891291308
$4,935.38
in general payments reported to CMS, 2019-2025
32 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.32 · 2021: $122 · 2022: $1,096 · 2023: $1,220 · 2024: $1,315 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.20 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $557.75 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $441.82 | 2022-2025 | |
| Novo Nordisk INC | $255.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $240.28 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $197.66 | 2022-2025 | Farxiga |
| Amgen INC. | $179.08 | 2023-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.15 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.40 | 2023-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $136.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $125.04 | 2023-2024 | |
| Glaxosmithkline, LLC. | $116.43 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $91.83 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.59 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $80.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $79.56 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $63.61 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $55.72 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $40.37 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $36.20 | 2024-2025 | Inspire |
| Dynavax Technologies Corporation | $32.64 | 2023-2024 | Heplisav-B |
| Astellas Pharma US INC | $31.80 | 2023-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $28.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.66 | 2022 | |
| Daiichi Sankyo INC. | $19.59 | 2022 | |
| Tris Pharma INC | $19.05 | 2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $18.77 | 2023 | Auvelity |
| Collegium Pharmaceutical, INC. | $18.13 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.08 | 2023 | Quviviq |
| Medtronic, INC. | $14.20 | 2022 | |
| Genentech USA, INC. | $12.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vanderloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.